Table 2.
Advantages | Disadvantages | Other considerations |
---|---|---|
• Low burden on participants and trial sites | • Endpoints limited to those captured in the data source. Complex clinical, performance-based, and imaging measures often not captured | • Participant consent |
• Comparatively low cost to primary data collection | • Endpoints need to be validated and may not be available across all jurisdictions of interest | • Nature of linkage (probabilistic or deterministic) |
• May minimize selection bias and loss to follow-up if all participants in prior trial agree to participate 51 | • Healthcare use may differ due to participant characteristics unrelated to the intervention | • Completeness and accuracy • Timing of extensive phase relative to parent trial |
• Can establish external comparator group 52 | • Availability of standardized definitions for variables to be used 53 | |
• Ability to capture outcomes non-traditional outcomes such as admission to long-term care and use of social services | • Time and administrative burden of data access and regional variation in access processes |